AATM on Facebook

Promotion of Home Telehealth Services, and Development of Mobile eHealth Applications in Armenia.

Among AATM’s plans for strategic development of health ICT in Armenia special place is devoted to remote patients’ monitoring and mobile (wireless) eHealth technologies. Importance of home telehealth lies in better management of chronic conditions and maintenance of health status in target groups of patients. Mobile telehealth (mHealth) emerges as one of the most promising areas of development in health ICT. 

In June 2012 AATM established cooperation with a telehealth and mHealth equipment producer company MegaKoto from Finland, and mHealth services provider Mobile Cardio from The Netherlands aiming to develop Mobile ECG Telemonitoring system for local cardiology clinics. The system consists of the central data server connected via dedicated lines with monitoring workstations installed at cardiology institutions and clinics, and lightweight highly portable single lead ECG sensors coupled via Bluetooth with Android smart phones with special application preinstalled. The sensor is reading ECG signal and sending it to the phone’s app, which uploads the data onto the server through mobile broadband connection. The monitoring workstation receives the signal in real time from the server, and displays it on large LED screens, for 7/24 live ECG monitoring by dedicated personnel. Besides that, authorized physicians are able to access their patients’ ECG data on the server, both live-streamed and stored, via special Web Access platform from any device connected to Internet. Thus, the system allows any person with heart problem to remain under ECG-surveillance 7/24, theoretically as long as the cardiologist deems necessary. Such breakthrough telemonitoring technology is being made available for Armenian population for the first time ever. The initial installations are already done (including the server and one monitoring workstation at one of the country’s leading cardiology facilities); the system has been tested in real life patients, and should now enter the commercial exploitation phase.